Methods for alleviating statin myopathy
View Patent ↗Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increased risk for diabetes, or cumulative trauma disorder, comprising administration of β-hydroxy β-methylbutyrate (HMB) to an individual taking a statin. Also disclosed are methods and compositions for alleviating acute rhabdomyolysis comprising administration of HMB. The disclosure further provides uses of HMB in combination with a statin to alleviate side effects of statin administration.
1. A method for alleviating one or more side effects of statin administration, the method comprising supplementing statin administration with administration of a therapeutically effective amount of β-hydroxy β-methylbutyrate (HMB).
2. The method of claim 1 , wherein the one or more side effects of statin administration are myopathic or myalgic side effects, short-term memory loss, elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels, glucose intolerance, hyperglycemia, increased risk for diabetes, or cumulative trauma disorder.
3. The method of claim 1 , wherein HMB is administered at a dosage of approximately 2.0 to 4.0 grams/day.
4. The method of claim 3 , wherein HMB is administered at a dosage of approximately 3.0 grams/day.
5. The method of claim 4 , wherein HMB is administered at a dosage of approximately 4.0 grams/day.
6. The method of claim 1 , wherein HMB is administered 1 to 5 times per day.
7. The method of claim 6 , wherein HMB is administered 3 times per day.
8. The method of claim 6 , wherein HMB is administered 2 times per day.
9. The method of claim 1 , wherein the statin is atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
10. The method of claim 9 , wherein the statin is rosuvastatin.
11. The method of claim 1 , wherein HMB is administered as calcium HMB monohydrate.
12. The method of claim 1 , wherein HMB is administered as HMB free acid.
13. A pharmaceutical formulation comprising a statin and a statin side effect-alleviating amount of β-hydroxy β-methylbutyrate (HMB).
14. The pharmaceutical formulation of claim 13 , wherein the statin is atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin.
15. The pharmaceutical formulation of claim 14 , wherein the statin is rosuvastatin.
16. The pharmaceutical formulation of claim 13 , wherein the formulation comprises statin and HMB at a ratio that is approximately 0.001 to 0.1 by weight.
17. The pharmaceutical formulation of claim 13 , wherein the formulation comprises statin and HMB at a ratio that is approximately 0.01 by weight.
18. The pharmaceutical formulation of claim 13 , comprising from about 1.0 gram to about 4.0 grams HMB.
19. The pharmaceutical formulation of claim 13 , wherein HMB is calcium HMB monohydrate.
20. The pharmaceutical formulation of claim 13 , wherein HMB is HMB free acid.
21. A method for treating acute rhabdomyolysis in a patient, the method comprising administering a therapeutically effective amount of β-hydroxy β-methylbutyrate (HMB) to the patient.
22. The method of claim 21 , wherein HMB is administered at a dosage of about 6 grams/day to about 12 grams/day.
23. The method of claim 22 , wherein HMB is administered at a dosage of about 12 grams/day.
24. The method of claim 23 , wherein HMB is HMB free acid.
25. The method of claim 21 , wherein HMB is administered for at least three days.